Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 Combined With Liver Directed Therapy in mCRPC
NCT07145177Phase 1Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Mar 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of California, San Francisco. Primary endpoints: Percentage of participants with treatment emergent adverse events up to 12 months and Objective Response Rate up to 12 months. Started Mar 2026; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07145177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145177.